Contact Person
    Helen Pettersson

    Senior Project Manager
    Email: hp@mva.org
    Phone: (M) +45 2337 0040
    LinkedIn

    MVA R&D Network Meeting

    Now is the time to get involved and take advantage of the four largest assets for life science research and innovation of our region: MAX IV, ESS, DESY and European XFEL!
    Welcome to Medicon Valley Alliance R&D Network and our 4th meeting!

    Are you from the Biotech, Medtech, or Pharma industry or academia and are interested in learning how to make use of the largest assets we have in our region for life science innovation and research? Are you a regional development actor and representative from the health care system and wish to discuss how we can face the global challenges of improving health and healthcare solutions?

    Medicon Valley Alliance (MVA), together with Hanseatic League of Science (HALOS), invites you to participate in MVA R&D network meeting on the 21st of November. Join the meeting and take the chance to learn more about how your organization can benefit from the large facilities! In addition to presentations from companies, facilities, academia, and funding stakeholders, the meeting will include a discussion forum and a networking session with posters from HALOS partner organizations. Now is the time to get involved in and be part of a new era for life science research and innovation in our region as well as globally.

    Date: 21 November, 2019
    Time: 17:00 – 20:00
    Host: Hanseatic League of Science (HALOS)
    Venue: Medicon Village, Auditorium, Scheelevägen 2, 223 63 Lund

    Sign up

    HALOS
    HALOS is a newly started Öresund-Kattegat-Skagerack (ÖKS) interreg EU funded project with stakeholders from academia, regional development actors, research facilities and industry. HALOS will build a unique collaboration between Hamburg and South-West Scandinavia, bring together the four unique research facilities MAX IV, ESS, DESY and European XFEL, and create a centre for integrated, world-leading Life Science innovation and research.

    The network
    MVA R&D Network is a professional and social network for C-level R&D executives (CSOs, CMOs, VPs), university professors and PIs, and top-level managers in the hospital sector. The network focuses on best practice and current challenges for industry-academia collaboration and the commercialization of R&D in the Medicon Valley region. 
    The network is free of charge and is limited to Medicon Valley Alliance members. Non-member organizations and companies are welcome to attend one network event to evaluate whether joining the network is relevant. If so, becoming a member of Medicon Valley Alliance will automatically allow you to join the Medicon Valley Alliance R&D Network.

    Program
    Will be contiounsly updated

    Moderator: Anna Stenstam, CEO, CR Competence

    17.00 – 17.30 Registration, poster session, networking and a bite to eat
    17.30 – 17.35 Welcome 
    Petter Hartman, CEO, Medicon Valley Alliance
    Kajsa Paulsson, Project Manager, HALOS
    17.35 – 17.40 Patenting protein crystal structures – how and why (not)?

    Peter Holm, Partner, European Patent Attorney, HØIBERG
    17.40-19.10

    Why & How – success stories, acces models (8-minute presentations)
    What are the possibilities with the facilities and the different ways to get access to the facilities?
    Listen to companies, industry portals and academia sharing their success stories and hear about different access models.

    Collaborations for increased utilization and capacity in industry
    Rebecca Hollertz, Program Manager, Vinnova

    Transforming neutron and X-ray science to industrial innovation. Mission impossible?
    Jimmy Binderup Andersen, CEO, Scientific Innovation & Senior Officer Industry and Innovation, ESS

    MAX IV Laboratory for Life Science
    Selma Maric, Industrial Relations, MAX IV

    AstraZeneca’s experiences in large scale facilities – tackle drug delivery challenges
    Susanna Abrahmsén-Alami, Principal Scientist, AstraZeneca

    Utilizing large scale facilities- examples from Novo Nordisk
    Gerd Schluckebier, Principal Scientist, Novo Nordisk A/S

    3D structure determination in antibody drug development
    Laura von Schantz, Director Antibody engineering, Alligator Bioscience AB

    Contract crystallography – how does it work
    Björn Walse, CEO, SARomics Biostructures AB

    Data collection at synchrotrons
    Holger von Moeller, CEO, moloX GmbH

    X-ray phase contrast zoom tomography as a novel tool to visualize human peripheral nerves
    Lars B. Dahlin, Professor, Lund University

    19.10-19.30 Panel discussion/questions from the audience
    How do we make the most of the facilities and what do YOU need to be able to get involved and take advantage of them?
    19.30 Concluding remarks
    Kajsa Paulsson, Project Manager , HALOS
    19.30 – 20.00 Networking, poster session & refreshments

    For more information please contact Senior Project Manager Helen Pettersson: hp@mva.org

    Host and sponsor
     Sponsors  

     

    MVA R&D Network is managed by In collaboration with